The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $41.07, representing a +0.32% change from its previous close. These five geonomics and synthetic biology stocks are likely to ...
The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...
A first patient has been treated in a trial of an Allergan and Editas drug based on CRISPR/Cas9, a technology that allows genes to be manipulated inside the body. The two companies claim AGN ...